Table of Contents
Few pharmaceutical stories have generated as much confusion — and patient frustration — as the semaglutide shortage saga. From 2022 through early 2025, compounding pharmacies legally provided a lower-cost alternative to brand-name Ozempic and Wegovy for millions of patients who couldn't access or afford the originator products. Then, when Novo Nordisk restored supply and the FDA declared the shortage resolved, the rules changed — dramatically.
If you're currently on compounded semaglutide, considering starting it, or wondering what your options are in 2025 and beyond, this article provides a clear, honest breakdown of where things stand — and what it means for your weight loss treatment.
The Semaglutide Shortage: Background
Semaglutide — the active ingredient in Ozempic (diabetes) and Wegovy (weight loss) — exploded in demand following viral media coverage and clinical trial results showing unprecedented weight loss outcomes. Novo Nordisk, the sole manufacturer, was unable to scale production fast enough to meet demand. The FDA placed semaglutide on its Drug Shortage Database, where it remained for nearly three years.
Drug shortages trigger a specific provision in the Federal Food, Drug, and Cosmetic Act (FD&C Act): when a drug is on the FDA shortage list, compounding pharmacies — specifically 503B outsourcing facilities — are permitted to produce compounded versions of that drug even if it's commercially available. This is what allowed the compounded semaglutide market to legally emerge and expand so rapidly during 2022–2024.
At peak shortage, it's estimated that hundreds of thousands of patients were receiving compounded semaglutide through telehealth platforms — often at significantly lower monthly costs than brand-name alternatives with insurance barriers.
Shortage Timeline: 2022–2025
Surging demand following Wegovy's approval for weight loss outstrips Novo Nordisk's manufacturing capacity. Compounding pharmacies begin legally producing compounded semaglutide.
Telehealth platforms proliferate. Compounded semaglutide becomes widely available at $150–$400/month vs. $1,300+ list price for branded versions. Millions of patients access treatment through this pathway.
Novo Nordisk expands manufacturing. FDA begins indicating the shortage may be resolved. Legal challenges and lobbying from compounding industry ensue. The FDA ultimately maintains shortage status through late 2024.
FDA removes semaglutide from the shortage database. 503B outsourcing facilities are given a compliance deadline to stop compounding semaglutide. Legal battles continue. 503A pharmacy rules also tighten under updated guidance.
503A vs. 503B Compounding Pharmacies Explained
To understand what happened to compounded semaglutide, you need to understand the two types of compounding pharmacies operating under federal law:
| Feature | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Regulated by | Primarily state boards of pharmacy | FDA (federally registered) |
| Prescription required? | Yes — patient-specific prescription from licensed prescriber | No — can bulk manufacture without patient-specific Rx |
| Scale | Individual or small batch | Large-scale production and distribution |
| Shortage exemption | Limited — complex legal questions apply | Explicitly permitted to compound shortage drugs |
| Post-shortage status | Restricted from copying commercially available drugs | Must cease compounding once shortage resolved |
| Quality standards | USP <795> and <797> | Current Good Manufacturing Practices (cGMP) |
"The compounding pathway provided access to life-changing medication for millions of patients who couldn't afford brand-name prices. Now the landscape is shifting — and patients deserve clarity about what that means for them."
— Truventa Medical Clinical TeamWhat Happened to Compounded Semaglutide?
When the FDA declared the semaglutide shortage resolved in early 2025, the legal basis for large-scale compounding through 503B facilities was eliminated. The FDA set a compliance date by which 503B outsourcing facilities were required to stop bulk-producing compounded semaglutide. Companies that continued after that date faced FDA enforcement action.
The 503A landscape is more nuanced. 503A pharmacies are generally prohibited from compounding drugs that are essentially copies of commercially available products — but they may compound for specific patients when there is a demonstrated clinical need (such as a different dose, inactive ingredient, or route of administration not available commercially). The FDA's guidance on this has been contested in court by compounding industry groups, creating an ongoing legal gray area.
Several large telehealth companies that had built their models around compounded semaglutide were forced to rapidly pivot — informing patients of the change, transitioning to tirzepatide, or discontinuing compounded GLP-1 offerings entirely. This caused significant disruption for existing patients mid-treatment.
Concerned About Your Current Medication Supply?
Truventa's physicians can review your options — including tirzepatide — and help you continue your weight loss progress without interruption.
Talk to a Truventa Physician →Current Availability in 2025–2026
As of 2026, the availability of compounded semaglutide for most patients has been significantly restricted. Here's what the landscape looks like:
- 503B compounded semaglutide: No longer legally available through compliant 503B outsourcing facilities for standard patients. Enforcement is ongoing against facilities that continued compounding after the FDA deadline.
- 503A compounded semaglutide: Theoretically available in narrow circumstances through 503A pharmacies, but most compliant pharmacies have limited this to cases where there is a documented clinical need for a modified formulation. Generic semaglutide is not yet available, which complicates the "essentially a copy" analysis.
- Brand-name semaglutide (Ozempic/Wegovy): Now more widely available due to restored supply. However, list prices remain very high without insurance, and insurance authorization for weight loss (Wegovy) can be challenging. Manufacturer savings programs may help qualified patients.
- Legal status remains in flux: Multiple lawsuits challenging the FDA's shortage resolution declaration are ongoing. Some rulings have provided temporary reprieves. Patients should stay in close communication with their provider about the current status.
💡 Important Note on "Research Chemical" Semaglutide
Some websites continue to sell semaglutide labeled as "not for human use" or as a "research chemical." These products are unregulated, have not been tested for human safety or sterility, and should be avoided entirely. They are not the same as pharmacy-compounded medications and pose significant health risks.
How Truventa Medical Sources Its Medications
Truventa Medical works exclusively with licensed, accredited compounding pharmacies and pharmaceutical suppliers that operate in full compliance with applicable state and federal regulations. We continuously monitor the evolving regulatory landscape and adjust our formulary accordingly.
Our commitment to patients includes:
- Proactive communication: When regulations change affecting a patient's current medication, we notify them promptly and present alternative options before any disruption in care.
- Compliance-first sourcing: We work only with pharmacies that meet rigorous quality standards, including appropriate accreditation and testing protocols.
- Seamless transitions: For patients who may need to transition from one medication to another, our physicians manage the process to minimize disruption to your weight loss progress.
Tirzepatide: The Leading Alternative
For many patients, tirzepatide (the active ingredient in Mounjaro and Zepbound) is an excellent alternative — and in some ways, an upgrade. Tirzepatide is a dual agonist that activates both GLP-1 and GIP receptors, producing even more potent weight loss effects than semaglutide in head-to-head clinical data.
| Semaglutide (Wegovy) | Tirzepatide (Zepbound) | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual agonist |
| Average weight loss | ~14.9% (STEP 1) | ~20.9% at highest dose (SURMOUNT-1) |
| Dosing frequency | Once weekly | Once weekly |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Compounded availability | Significantly restricted post-shortage resolution | Currently more available through compounding (shortage status varies) |
| Side effect profile | GI-focused (nausea, constipation, vomiting) | Similar GI effects; some patients report better GI tolerance |
For patients transitioning from semaglutide to tirzepatide, the switch is generally straightforward with physician guidance on dose equivalency. Many patients report similar or improved tolerability with tirzepatide, and the superior average weight loss outcomes make it a compelling option.
Frequently Asked Questions
Is compounded semaglutide still legal in 2025?
The legal landscape for compounded semaglutide changed significantly in 2025 when the FDA declared the semaglutide shortage resolved. Under federal law, 503B outsourcing facilities lost their ability to compound copies of semaglutide once the shortage ended. 503A pharmacies operate under a different legal framework but face their own restrictions. The situation involves ongoing litigation and regulatory changes — patients should verify current compliance with their provider.
What is the difference between 503A and 503B compounding pharmacies?
503A pharmacies are traditional compounding pharmacies that compound medications for individual patients based on a valid prescription. They are regulated primarily by state boards of pharmacy. 503B outsourcing facilities are larger-scale, FDA-registered operations that can manufacture and distribute compounded drugs in bulk. During a drug shortage, 503B facilities were permitted to compound copies of shortage drugs — but that permission was removed when the FDA resolved the shortage.
What happened to all the compounded semaglutide that was available?
During the shortage period (2022–2025), compounding pharmacies legally provided compounded semaglutide at lower cost. When the FDA declared the shortage resolved, 503B facilities were required to stop producing compounded semaglutide. Many telehealth companies that relied on compounded semaglutide had to pivot their offerings, causing confusion and disruption for existing patients.
Is tirzepatide a good alternative to semaglutide?
Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist that has shown even greater average weight loss than semaglutide in head-to-head clinical data — approximately 20% body weight loss in the SURMOUNT-1 trial vs. 14.9% for semaglutide in STEP 1. Many patients who have plateaued on semaglutide or who are looking for strong initial results find tirzepatide to be an effective alternative. Truventa Medical offers tirzepatide as part of its weight loss program.
Keep Your Weight Loss Momentum Going
Whether you're transitioning from semaglutide or starting fresh, Truventa's physicians will guide you to the right medication for your goals. No insurance required.
Start Your Free Consultation →